Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Moving forward in good KarMMa in myeloma

Giada Bianchi

Blood (2024) 144 (23): 2367–2369.

https://doi.org/10.1182/blood.2024026428

Published: 2024

Journal Articles

Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis

Pedro G Vianna, Shahrier Hossain, Shannon Miller, Annemarie Rossi, Sarah AM Cuddy, Rodney H Falk, Jacob P. Laubach, Giada Bianchi

Blood (2024) 144 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2024-200933

Published: 2024

Journal Articles

Systematic Annotation of Secretory Pathway Genes As a Discovery Tool for New Therapeutic Targets in AL Amyloidosis

Brendan Saunders, Carlos Quetglas, Dirk Fasshauer, Suzanne Elsasser, Giada Bianchi

Blood (2024) 144 (Supplement 1): 6835.

https://doi.org/10.1182/blood-2024-210683

Published: 2024

Journal Articles

Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Cybord or Daracybord

Brendan Saunders, Foteini Theodorakakou, Benjamin Evans, Samuel Boullt, Despina Fotiou, Meletios Dimopoulos, Efstathios Kastritis, Giada Bianchi

Blood (2024) 144 (Supplement 1): 6882.

https://doi.org/10.1182/blood-2024-204612

Published: 2024

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1928.

https://doi.org/10.1182/blood-2024-203684

Published: 2024

Journal Articles

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Nadine Abdallah, Jay R. Hydren, Mason S. Barnes, Andrew Wood, Sascha Alexander Tuchman, Jeffrey A. Zonder, Giada Bianchi, Heather J. Landau, Muhamed Baljevic, James E. Hoffman, Ana M. Sahagun Sanchez Aldana, Jorge Arturo Hurtado Martinez, Jennifer M. Ahlstrom, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 5143.

https://doi.org/10.1182/blood-2024-208737

Published: 2024

Journal Articles

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood (2024) 143 (25): 2612–2626.

https://doi.org/10.1182/blood.2023022777

Published: 2024

Includes: Supplemental data

Journal Articles

A SNAP23-Dependent SNARE Complex Mediates Free Light Chain Secretion in AL Amyloidosis and Multiple Myeloma and Its Blockade Triggers a Terminal Unfolded Protein Response and Massive Apoptosis

Emre Karayol, Maria Moscvin, Tianzeng Chen, Peter G. Czarnecki, Annamaria Gulla, Kenneth C. Anderson, Giada Bianchi

Blood (2023) 142 (Supplement 1): 4662.

https://doi.org/10.1182/blood-2023-177714

Published: 2023

Journal Articles

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

Paolo Lopedote, Alfredo Marchetti, Benjamin Evans, Tianzeng Chen, Maria Moscvin, Niccolò Bolli, Giada Bianchi

Blood (2023) 142 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2023-190905

Published: 2023

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Blood (2023) 142 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2023-180224

Published: 2023

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10180–10181.

https://doi.org/10.1182/blood-2022-165512

Published: 2022

Journal Articles

Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma

Annamaria Gulla, Eugenio Morelli, Mehmet K. Samur, Megan Johnstone, Cirino Botta, Delaney Vinaixa, Marcello Turi, Mariateresa Fulciniti, Kenneth Wen, Selma Cifric, Srikanth Talluri, Giada Bianchi, Rao Prabhala, Paul G. Richardson, Dharminder Chauhan, Ruben D. Carrasco, Teru Hideshima, Nikhil C Munshi, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 7114–7115.

https://doi.org/10.1182/blood-2022-162653

Published: 2022

Journal Articles

Sustained minimal residual disease in myeloma

Giada Bianchi

Blood (2022) 139 (4): 469–471.

https://doi.org/10.1182/blood.2021013199

Published: 2022

Journal Articles

Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma

Annamaria Gulla, Eugenio Morelli, Mehmet K. Samur, Cirino Botta, Megan Johnstone, Giada Bianchi, Mariateresa Fulciniti, Leona Yamamoto, Rao Prabhala, Kenneth Wen, Paul G. Richardson, Yu-Tzu Tai, Dharminder Chauhan, Teru Hideshima, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 891.

https://doi.org/10.1182/blood-2021-148621

Published: 2021

Journal Articles

Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy

Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Eileen Regan, Efstathios Kastritis, Meletios A. Dimopoulos, Paul G. Richardson, Giada Bianchi

Blood (2021) 138 (Supplement 1): 2708.

https://doi.org/10.1182/blood-2021-153229

Published: 2021

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1650.

https://doi.org/10.1182/blood-2021-146866

Published: 2021

Journal Articles

Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response

Maria Moscvin, Tianzeng Chen, Peter G. Czarnecki, Annamaria Gulla, Kenneth C. Anderson, Giada Bianchi

Blood (2021) 138 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2021-149768

Published: 2021

NARROW

Moving forward in good KarMMa in myeloma

Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis

Systematic Annotation of Secretory Pathway Genes As a Discovery Tool for New Therapeutic Targets in AL Amyloidosis

Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Cybord or Daracybord

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

A SNAP23-Dependent SNARE Complex Mediates Free Light Chain Secretion in AL Amyloidosis and Multiple Myeloma and Its Blockade Triggers a Terminal Unfolded Protein Response and Massive Apoptosis

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma

Sustained minimal residual disease in myeloma

Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma

Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only